Cargando…

Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency

BACKGROUND: One strategy being pursued to clear latently infected cells that persist in people living with HIV (PLWH) on antiretroviral therapy (ART) is to activate latent HIV infection with a latency reversing agent (LRA). Surrogate markers that accurately measure virus production following an LRA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zerbato, Jennifer M., Khoury, Georges, Zhao, Wei, Gartner, Matthew J., Pascoe, Rachel D., Rhodes, Ajantha, Dantanarayana, Ashanti, Gooey, Megan, Anderson, Jenny, Bacchetti, Peter, Deeks, Steven G., McMahon, James, Roche, Michael, Rasmussen, Thomas A., Purcell, Damian FJ, Lewin, Sharon R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920823/ https://www.ncbi.nlm.nih.gov/pubmed/33647768 http://dx.doi.org/10.1016/j.ebiom.2021.103241

Ejemplares similares

Diverse effects of interferon alpha on the establishment and reversal of HIV latency
por: Van der Sluis, Renée M., et al.
Publicado: (2020)

Memory CD4(+) T cells that co-express PD1 and CTLA4 have reduced response to activating stimuli facilitating HIV latency
por: Rasmussen, Thomas A., et al.
Publicado: (2022)

HIV DNA persists in hepatocytes in people with HIV-hepatitis B co-infection on antiretroviral therapy
por: Zerbato, Jennifer M., et al.
Publicado: (2022)

Persistence of envelopes in different CD4(+) T-cell subsets in antiretroviral therapy-suppressed people with HIV
por: Gartner, Matthew J., et al.
Publicado: (2023)

GITR activation ex vivo impairs CD8 T cell function in people with HIV on antiretroviral therapy
por: Gubser, Céline, et al.
Publicado: (2023)

Intrahepatic CXCL10 is strongly associated with liver fibrosis in HIV-Hepatitis B co-infection
por: Singh, Kasha P., et al.
Publicado: (2020)

The RNA-Binding Proteins SRP14 and HMGB3 Control HIV-1 Tat mRNA Processing and Translation During HIV-1 Latency
por: Khoury, Georges, et al.
Publicado: (2021)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

The role of latency reversal in HIV cure strategies
por: Tanaka, Kiho, et al.
Publicado: (2022)

Broad activation of latent HIV-1 in vivo
por: Barton, Kirston, et al.
Publicado: (2016)

Human Immunodeficiency Virus (HIV)–Infected CCR6(+) Rectal CD4(+) T Cells and HIV Persistence On Antiretroviral Therapy
por: Anderson, Jenny L, et al.
Publicado: (2020)

Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells
por: Saleh, Suha, et al.
Publicado: (2011)

A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls
por: McMahon, James H., et al.
Publicado: (2021)

Markers of Immune Activation and Inflammation Are Associated with Higher Levels of Genetically-Intact HIV in HIV-HBV Co-Infected Individuals
por: Wang, Xiao Qian, et al.
Publicado: (2022)

Adaptation of Droplet Digital PCR-Based HIV Transcription Profiling to Digital PCR and Association of HIV Transcription and Total or Intact HIV DNA
por: Tumpach, Carolin, et al.
Publicado: (2023)

Factors associated with weak positive SARS-CoV-2 diagnosis by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR)
por: Rawat, Priyank, et al.
Publicado: (2022)

HIV latency reversing agents act through Tat post translational modifications
por: Khoury, Georges, et al.
Publicado: (2018)

PD-1 blockade potentiates HIV latency reversal ex vivo in CD4(+) T cells from ART-suppressed individuals
por: Fromentin, Rémi, et al.
Publicado: (2019)

Relevance of multiply spliced HIV-1 RNA measurement in assessing the efficacy of viral latency-reversing strategies
por: Doria, Margherita
Publicado: (2021)

Understanding Factors That Modulate the Establishment of HIV Latency in Resting CD4+ T-Cells In Vitro
por: Anderson, Jenny L., et al.
Publicado: (2016)

Unequal distribution of genetically-intact HIV-1 proviruses in cells expressing the immune checkpoint markers PD-1 and/or CTLA-4
por: Fisher, Katie, et al.
Publicado: (2023)

Latency reversal plus natural killer cells diminish HIV reservoir in vivo
por: Kim, Jocelyn T., et al.
Publicado: (2022)

Novel ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo
por: Bullen, C. Korin, et al.
Publicado: (2014)

Longitudinal analysis of subtype C envelope tropism for memory CD4(+) T cell subsets over the first 3 years of untreated HIV-1 infection
por: Gartner, Matthew J., et al.
Publicado: (2020)

Inconsistent reversal of HIV-1 latency ex vivo by antigens of HIV-1, CMV, and other infectious agents
por: Vollbrecht, Thomas, et al.
Publicado: (2020)

Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir
por: Das, Biswajit, et al.
Publicado: (2018)

HIVed, a knowledgebase for differentially expressed human genes and proteins during HIV infection, replication and latency
por: Li, Chen, et al.
Publicado: (2017)

Bioinformatics and HIV Latency
por: Ciuffi, Angela, et al.
Publicado: (2015)

HIV-1-Based Virus-like Particles that Morphologically Resemble Mature, Infectious HIV-1 Virions
por: Gonelli, Christopher A., et al.
Publicado: (2019)

Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo
por: Nixon, Christopher C., et al.
Publicado: (2020)

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
por: Pinkevych, Mykola, et al.
Publicado: (2015)

Soluble immune checkpoints as correlates for HIV persistence and T cell function in people with HIV on antiretroviral therapy
por: Chiu, Chris Y., et al.
Publicado: (2023)

The BAF complex and HIV latency
por: Mahmoudi, Tokameh
Publicado: (2012)

HIV-1 Latency and Latency Reversal: Does Subtype Matter?
por: Sarabia, Indra, et al.
Publicado: (2019)

AP-1/c-Fos supports SIV and HIV-1 latency in CD4 T cells infected in vivo
por: Cobos Jiménez, Viviana, et al.
Publicado: (2023)

Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
por: Pinkevych, Mykola, et al.
Publicado: (2016)

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation
por: Gunst, Jesper D, et al.
Publicado: (2019)

Anti-HIV Antibody Responses and the HIV Reservoir Size during Antiretroviral Therapy
por: Lee, Sulggi A., et al.
Publicado: (2016)

Temporal transcriptional response to latency reversing agents identifies specific factors regulating HIV-1 viral transcriptional switch
por: Venkatachari, Narasimhan J., et al.
Publicado: (2015)

Limitations of dual‐fluorescent HIV reporter viruses in a model of pre‐activation latency
por: Kim, Youry, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ec72ai6276n0mi29bb2fsftbc6